Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

Early identification of individuals at a high risk for MASLD could “profoundly transform” intervention strategies, experts say.

Major drug companies are beginning to deliver their first-quarter readouts to Wall Street analysts, revealing their ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Shares of Merck and Verizon are retreating Friday morning, sending the Dow Jones Industrial Average into negative territory.